Takashi Kohno
A5025520229- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Lung Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Chromatin Remodeling and Cancer
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- MicroRNA in disease regulation
- Genomics and Chromatin Dynamics
- Microtubule and mitosis dynamics
- interferon and immune responses
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Chemokine receptors and signaling
- Ubiquitin and proteasome pathways
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Cancer-related gene regulation
- Molecular Biology Techniques and Applications
National Cancer Centre Japan
2016-2025
National Cancer Research Institute
2014-2024
Japan Clinical Cancer Research Organization
2013-2024
Tokyo National Hospital
2016-2024
Kyorin University
2022-2024
Kyorin University Hospital
2024
The University of Tokyo
2008-2023
Jikei University School of Medicine
2019-2023
Komatsu (Japan)
2022-2023
National Cancer Center Hospital East
2012-2022
Abstract Activation of the EGFR, KRAS, and ALK oncogenes defines 3 different pathways molecular pathogenesis in lung adenocarcinoma. However, many tumors lack activation any pathway (triple-negative adenocarcinomas) posing a challenge for prognosis treatment. Here, we report an extensive genome-wide expression profiling 226 primary human stage I–II adenocarcinomas that elucidates characteristics harbor mutations or mutations, is, triple-negative adenocarcinomas. One hundred seventy-four...
Purpose Exosomal microRNAs (miRNAs) have been attracting major interest as potential diagnostic biomarkers of cancer. The aim this study was to characterize the miRNA profiles serum exosomes and identify those that are altered in colorectal cancer (CRC). To evaluate their use biomarkers, relationship between specific exosomal levels pathological changes patients, including disease stage tumor resection, examined. Experimental Design Microarray analyses miRNAs exosome-enriched fractions...
Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility utility NGS-based analysis 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 types) advanced solid tumors, all which were...
A subset (1% to 5%) of non-small-cell lung carcinomas harbors the EML4-ALK fusion gene. Data from previous studies on histomorphology ALK-rearranged cancer are inconsistent, and specific histologic parameters that characterize this how accurately such predict underlying ALK abnormality remain uncertain. To answer these questions, we performed a comprehensive analysis 54 surgically resected, extensively sampled compared them with 100 consecutive resections ALK-wild-type cancers. All cases...
The occurrence of inactivating mutations in SWI/SNF chromatin-remodeling genes common cancers has attracted a great deal interest. However, mechanistic strategies to target tumor cells carrying such are yet be developed. This study proposes synthetic-lethality therapy for treating deficient the catalytic (ATPase) subunit, BRG1/SMARCA4. strategy relies upon inhibition BRM/SMARCA2, another subunit with BRG1-related activity. Immunohistochemical analysis cohort non-small-cell lung carcinomas...
Abstract Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma (IMA) of the lung, a malignant type lung which KRAS mutations frequently occur. Experimental Design: From an IMA cohort 90 cases, consisting 56 cases (62%) with and 34 without (38%), we conducted whole-transcriptome sequencing 32 IMAs, including 27 mutations. We used data to gene fusions, then performed functional analyses fusion products. Results: identified that occurred mutually exclusively...
A growing number of studies suggest critical tumor suppressor roles the SWI/SNF chromatin remodeling complex in a variety human cancers. The recent discovery SMARCA4-deficient thoracic sarcomas has added to list groups with SMARCA4 inactivating mutation. To better characterize these tumors and establish their nosological status, we undertook clinicopathological molecular analysis 12 compared them three potentially related disease entities. Eleven men one woman (aged 27-82 years, median 39...
Background Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk distant metastasis at every disease stage. We aimed to characterize genomic landscape LUAD identify mutation signatures associated with tumor progression. Methods Findings performed an integrative analysis, incorporating whole exome sequencing (WES), determination DNA copy number methylation, transcriptome for 101 samples from Environment And Genetics in Etiology (EAGLE) study....
The clinical importance of genetic testing BRCA1 and BRCA2 in breast, ovarian, prostate, pancreatic cancers is widely recognized. However, there insufficient evidence to include other cancer types that are potentially associated with management guidelines.To evaluate the association pathogenic variants additional their characteristics 100 914 individuals across 14 types.This case-control analysis identify included DNA samples information from 63 828 patients common 37 086 controls were...
Since June 2019, under the umbrella of national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive profiling (CGP) tests. The Ministry Health, Labour and Welfare (MHLW) constructed a network CGM hospitals (a total 233 institutes as July 1, 2022) established Center for Cancer Genomics Advanced Therapeutics (C-CAT), datacenter CGM. Clinical information data from CGP tests are securely transferred to C-CAT, which then generates "C-CAT Findings" reports...
Components of the SWI/SNF chromatin-remodeling complex, such as INI1, are inactivated in human cancer and, thus, act tumor suppressors. Here we screened for mutations entire coding sequence BRG1 (SMARCA4), which encodes ATPase 59 lung cell lines most common histopathological types. Mutations were detected 24% lines, many them cells commonly used research. All homozygous and predicted truncated proteins. The alterations significantly more frequent non-small-cell (NSCLC) type (13/37, 35%)...